SynthesisMedical oncology (Northwood, London, England)2026
Repurposing statins for the management of head and neck squamous cell carcinoma: A systematic review of preclinical and clinical evidence.
Synthesis in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statins are marketed as antihyperlipidemic drugs, have been repurposed in cancer management. Their repurposing is based on antiproliferative, apoptotic, and anti-metastatic properties. Head and neck cancer, including oral carcinoma, remains a global burden with limited advancements. Therefore, we study the preclinical and clinical advancements of statins and statins-loaded nanocarriers in head and neck cancer. Data were extracted from various sources, including PubMed, Scopus, and Web of Science. Publications reporting in vitro, in vivo, and clinical data were evaluated. Data will be extracted and assessed following PRISMA guidelines. Various statistical parameters, such as Risk Ratio and Odds Ratio, were computed to analyze the reported clinical trials. This systematic review provides evidence-based proof of the anticancer potential of statins. Research gaps and future perspectives have also been discussed.
Indexed as
Identifiers
42307682What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.